Curevac B.V. - CVAC STOCK NEWS

CureVac announces developments in patent litigation with Pfizer/BioNTech

CureVac announced the dosing of the first participant in the Phase 1 part of a combined Phase 1/2 study of multivalent, modified mRNA seasonal flu vaccine candidates developed in collaboration with GSK. The vaccine candidates address all four WHO-recommended flu strains. Preliminary data from a previous trial showed a favorable tolerability profile and strong immune responses. CureVac's mRNA capabilities position them well to develop and deliver seasonal flu vaccines.

CureVac N.V. (Nasdaq:CVAC) reported its financial results for the fourth quarter and full year 2022, showcasing a significant transformation in its operations driven by clinical advancements in COVID-19 and flu together with a broadened oncology footprint. The company achieved positive preliminary Phase 1 data for its modified COVID-19 candidate CV0501 and flu candidate Flu-SV-mRNA, demonstrating good tolerability and strong immune responses across age groups. CureVac ended 2022 with €495.8 million in cash, down from €811.5 million the previous year, driven by R&D expenditures. Revenue fell to €67.4 million from €103.0 million, primarily due to the cessation of collaborations and focused program adjustments. The operating loss for the year was €249.5 million, reflecting increased strategic investments.

CureVac N.V. (Nasdaq:CVAC), a biopharmaceutical company based in Tübingen, Germany, is set to report its fourth quarter and full-year 2022 financial results on April 25, 2023. The company will also offer business updates during a conference call at 3 p.m. CET / 9 a.m. EST. Interested parties can join via U.S. Toll-Free number or through international dial-in options. A live webcast will also be available on the CureVac website. This announcement follows CureVac's notable history in developing mRNA technology, including a partnership with GSK for vaccine development. With over 20 years of expertise, CureVac continues to build a robust clinical pipeline targeting various diseases.

CureVac N.V. (NASDAQ:CVAC) announced the results of its extraordinary general meeting held on March 28, 2023. Shareholders approved all proposals, including the appointment of Dr. Alexander Zehnder as CEO starting April 1, 2023, and Dr. Myriam Mendila as CDO, effective February 1, 2023. A detailed vote tabulation will be released soon. CureVac specializes in mRNA technology with over 20 years of expertise, focusing on developing vaccines and therapies for various diseases. The company collaborates with GSK on new mRNA product development.

CureVac (NASDAQ:CVAC) announced the successful closing of a $250 million follow-on public offering, comprising 27,027,028 common shares sold at a price of $9.25 each. The offering was facilitated by major financial institutions including Goldman Sachs, Jefferies, and SVB Securities. The proceeds are intended to support the company's mRNA technology initiatives, which include vaccines for infectious diseases and therapies for various conditions. CureVac’s innovative approach positions it well within the biopharmaceutical landscape, emphasizing its commitment to enhancing patient care through advanced mRNA solutions.

CureVac N.V. (NASDAQ:CVAC) announced a proposed public offering of $200 million of its common shares, with the option for underwriters to purchase up to 15% more within 30 days. The offering will be conducted under an automatically effective shelf registration statement filed with the SEC. Bookrunners include Goldman Sachs, Jefferies, and SVB Securities. CureVac specializes in mRNA technology, with plans for further product development, including COVID-19 vaccines in collaboration with GSK. The actual size and terms of the offering are subject to market conditions.